Scarica l'app Stockscreener
0.81
9.29%
-0.083
Pre-mercato:
.83
0.02
+2.47%
Precedente Chiudi:
$0.893
Aprire:
$0.8662
Volume 24 ore:
135.30K
Relative Volume:
0.33
Capitalizzazione di mercato:
$4.22M
Reddito:
-
Utile/perdita netta:
$-18.68M
Rapporto P/E:
-0.1095
EPS:
-7.3948
Flusso di cassa netto:
$-15.70M
1 W Prestazione:
-12.90%
1M Prestazione:
-22.86%
6M Prestazione:
-83.18%
1 anno Prestazione:
-94.92%
Intervallo 1D:
$0.7849
$0.875
Intervallo di 1 settimana:
$0.7849
$1.04
Portata 52W:
$0.7849
$16.20
Fibrobiologics Inc Stock (FBLG) Company Profile
Nome
Fibrobiologics Inc
Settore
Industria
Telefono
281-671-5150
Indirizzo
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.81 | 4.65M | 0 | -18.68M | -15.70M | -7.3948 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-24 | Iniziato | Maxim Group | Buy |
Fibrobiologics Inc Borsa (FBLG) Ultime notizie
FBLG Q1 2026 Earnings: Slight EPS Miss as Pre-Revenue Biotech Advances PipelineHigh Estimate Range - newsline.com
FibroBiologics (FBLG) Declines Amid Volatility, Nears Critical Support ZoneValue Area Low - newsline.com
FibroBiologics Inc. (FBLG) Slides 3% as Selling Pressure Tests Key Support ZoneEnding Diagonal - newsline.com
FIBROBIOLOGICS INC (FBLG) Stock Chart - ChartMill
FibroBiologics Inc. (FBLG) Q1 2026 Earnings: Narrow EPS Miss Highlights Pre-Revenue Biotech Challenges - newsline.com
FBLG: Phase 1/2 Trial of CYWC628 Underway - Zacks Small Cap Research
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial - Sahm
FibroBiologics begins dosing patients in diabetic ulcer trial By Investing.com - Investing.com South Africa
FibroBiologics begins dosing patients in diabetic ulcer trial - Investing.com UK
FibroBiologics (FBLG) Begins Clinical Trial for Diabetic Foot Ulcers Treatment - GuruFocus
Fibrobiologics Announces First Patients Dosed In Phase 1/2 Clinical Trial Evaluating Cywc628 For The Treatment Of Diabetic Foot Ulcers - TradingView
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers - The Manila Times
Experimental cell therapy for diabetic foot ulcers starts dosing patients - Stock Titan
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data? - Insider Monkey
10 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
FBLG Stock Price, Quote & Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting - Sahm
D. Boral Capital Maintains FibroBiologics (FBLG) Buy Recommendation - MSN
symbol__ Stock Quote Price and Forecast - CNN
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics files patent for oral fibroblast delivery system - Investing.com UK
FibroBiologics files patent for oral fibroblast delivery system By Investing.com - Investing.com Australia
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics - GlobeNewswire
Exclusive: FibroBiologics targets 2026 data readout after trial progress for diabetic foot ulcer study - MSN
TradingKey - TradingKey
Fibrobiologics explores use of fibroblast platform for hantavirus - BioWorld News
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - GlobeNewswire
Severe Hantavirus syndrome lacks drugs, FibroBiologics tests fibroblast therapy - Stock Titan
FibroBiologics, Inc. Files Form 8-K Announcing Material Definitive Agreement and Company Details - Minichart
FibroBiologics | 424B5: Prospectus - Moomoo
FBLG | FibroBiologics, Inc. Common Stock Executive Compensation - Quiver Quantitative
FibroBiologics Expands At-The-Market Equity Offering Capacity - TipRanks
FibroBiologics Grants Stock Options to Key Executives - The Globe and Mail
FibroBiologics (NASDAQ: FBLG) expands $7.5M at-the-market stock offering - Stock Titan
Fibrobiologics Inc Azioni (FBLG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fibrobiologics Inc Azioni (FBLG) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 03 '26 |
Buy |
0.41 |
18,200 |
7,373 |
5,942,275 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 02 '26 |
Buy |
0.35 |
17,428 |
6,152 |
5,924,075 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 04 '26 |
Buy |
0.38 |
15,872 |
6,006 |
5,958,147 |
| Davis Jason | Chief Financial Officer |
Mar 02 '26 |
Buy |
0.41 |
70,000 |
28,973 |
70,000 |
| GARCIA RUBEN A | General Counsel |
Feb 27 '26 |
Buy |
0.33 |
40,000 |
13,056 |
180,000 |
| GARCIA RUBEN A | General Counsel |
Dec 11 '25 |
Buy |
0.34 |
140,000 |
47,600 |
140,000 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):